Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).

被引：6
|
作者：
Arora, Sukeshi Patel
Tenner, Laura LaNiel
Sarantopoulos, John
Morris, Jay Larry
Longoria, Lisa
Liu, Qianqian
Michalek, Joel
Mahalingam, Devalingam
机构：
[1] UT Hlth San Antonio Canc Ctr, San Antonio, TX USA
[2] Univ Texas Hlth San Antonio, Mays Canc Ctr, Inst Drug Dev, San Antonio, TX USA
[3] Northwestern Univ, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.3551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3551
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase II study of cetuximab (Erbitux®) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Chang, Heung Moon
    Ryu, Min-Hoe
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 : S98 - S103
  • [32] Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
    Nakamura, Masato
    Aoyama, Toru
    Ishibashi, Keiichiro
    Tsuji, Akihito
    Takinishi, Yasutaka
    Shindo, Yoshiaki
    Sakamoto, Junichi
    Oba, Koji
    Mishima, Hideyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 29 - 36
  • [33] Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
    Masato Nakamura
    Toru Aoyama
    Keiichiro Ishibashi
    Akihito Tsuji
    Yasutaka Takinishi
    Yoshiaki Shindo
    Junichi Sakamoto
    Koji Oba
    Hideyuki Mishima
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 29 - 36
  • [34] Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
    Khan, Khurum
    Rata, Mihaela
    Cunningham, David
    Koh, Dow-Mu
    Tunariu, Nina
    Hahne, Jens C.
    Vlachogiannis, George
    Hedayat, Somaieh
    Marchetti, Silvia
    Lampis, Andrea
    Damavandi, Mahnaz Darvish
    Lote, Hazel
    Rana, Isma
    Williams, Anja
    Eccles, Suzanne A.
    Fontana, Elisa
    Collins, David
    Eltahir, Zakaria
    Rao, Sheela
    Watkins, David
    Starling, Naureen
    Thomas, Jan
    Kalaitzaki, Eleftheria
    Fotiadis, Nicos
    Begum, Ruwaida
    Bali, Maria
    Rugge, Massimo
    Temple, Eleanor
    Fassan, Matteo
    Chau, Ian
    Braconi, Chiara
    Valeri, Nicola
    GUT, 2018, 67 (08) : 1484 - 1492
  • [35] Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC): Planned interim efficacy and safety analysis.
    Arora, Sukeshi Patel
    Moseley, Jennifer L.
    Tenner, Laura LaNiel
    Arellano, Luisa
    Salazar, Mary
    Liu Qianqian
    Michalek, Joel
    Mahalingam, Devalingam
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [36] Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial.
    Napolitano, Stefania
    De Falco, Vincenzo
    Martini, Giulia
    Esposito, Lucia
    Famiglietti, Vincenzo
    Martinelli, Erika
    Ciardiello, Davide
    Marrone, Francesca
    Avallone, Antonio
    Cardone, Claudia
    De Stefano, Alfonso
    Montesarchio, Vincenzo
    Zampino, M. Giulia
    Bordonaro, Roberto
    Scartozzi, Mario
    Santini, Daniele
    Di Maio, Massimo
    Ciardiello, Fortunato
    Troiani, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 129 - 129
  • [37] NON-RANDOMIZED PHASE II STUDY COMPARING METRONOMIC REGIMENS OF CHEMOTHERAPY IN PATIENTS (PTS) WITH REFRACTORY METASTATIC COLORECTAL CANCER (MCRC)
    Chubenko, V. A.
    Protsenko, S. A.
    Mikhalychenko, T. D.
    Moiseyenko, F. V.
    Brezhnev, N. V.
    Novik, A. V.
    Volkov, N. M.
    Semenov, I. I.
    Moiseyenko, V. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 181 - 182
  • [38] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Lindsay, Sheila
    Nalla, Sneha
    Schwartz, Gabriel
    Whitman, Julia
    Zendejas, Patricia
    Zhang Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [39] Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) plus Imprime PGG (Imprime) plus bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
    Fakih, Marwan
    Cleary, James M.
    Hong, Yong Sang
    Kim, Tae-You
    Safyan, Rachael A.
    Allen, Simon
    Bailey, Lorna
    Cha, Edward
    Lenain, Christelle
    Lu, Danny
    Schulze, Jochen
    Shemesh, Colby S.
    Zimmermann, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results
    Passardi, Alessandro
    Fanini, Francesca
    Turci, Livia
    Foca, Flavia
    Rosetti, Paola
    Ruscelli, Silvia
    Gardini, Andrea Casadei
    Valgiusti, Martina
    Dazzi, Claudio
    Marangolo, Maurizio
    ONCOLOGIST, 2017, 22 (08): : 886 - +
12345